The main objectives for 2019 are to present topline results of the Phase 1-2 clinical study of CDNF, advance patient recruitment in the Phase 2 clinical study with Lymfactin, select a lead molecule for the formal development of the next generation xCDNF, and secure financing for the company's planned operations through the end of 2020.
'Our CDNF program aims to be the first disease-modifying treatment of Parkinson's disease.
recombinant BDNF (13.5 kDa, pI 9.43), human recombinant CDNF (18.5 kDa,
neurotrophic factors CDNF and MANF: structure, physiological functions
Finland-based Herantis Pharma has started a non-invasive cerebral dopamine neurotrophic factor (CDNF) development program to expand the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders, it was reported yesterday.
The company and the University of Helsinki have signed a licensing agreement offering Herantis globally, exclusive rights for the therapeutic application of a non-invasive CDNF approach based on a modification of the natural CDNF.
We hypothesized that salidroside promoted survival and proliferation of Schwann cells through the secretion of GDNF, BDNF, and CDNF
. In this study, we investigated the effect of salidroside on the survival, proliferation, and gene expression of Schwann cells to explore the underlying mechanism of the salidroside-induced neurotrophin secretion in SCs.
The Chairman CDNF
Faiz Muhammad Bhangar briefed the contesting candidates and masses about the programme and said that voting is the foundation of democracy; efforts should be made to motivate the voters to exercise their right of vote and ensure to increase the turn out and make the elections peaceful.
MANF is released from glial cells in the midbrain and is a member of the same growth factor family as CDNF
The move follows a recommendation from an independent Data Safety Monitoring Board (DSMB) which assessed the safety data of CDNF
on the first patients.
Of these, a subset will be given a placebo infusion instead of CDNF
, in a blinded manner.
Herantis Pharma plc (HEL: HRTIS) has received authorisation from the Medicines Agency of Sweden, MPA, to begin its first-in-human clinical study of its investigational product CDNF
for the treatment of Parkinson's disease, the company disclosed on Thursday.